1814 - FISH and GEP Based Prediction of Chromosomal Translocation Identifies Myeloma Patients Who Do Not Benefit From Bortezomib
197 - Combining Proteomics and Gene Expression Profiling Identifies Proteins/Genes Associated with Short Overall Survival in Multiple Myeloma
2910 - 18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials
2915 - DNA Flow Cytometry and Metaphase Cytogenetics Can Predict Progression of Asymptomatic Monoclonal Gammopathies (AMG) to Symptomatic Multiple Myeloma (MM)
2918 - Prognostic Significance of DNA/Cig Flow Cytometry Assay in the ‘’era’’ of Novel Therapies in Multiple Myeloma (MM)
3983 - Hyperhaploid Multiple Myeloma (MM): A Rare Karyotypic Subgroup Retaining Disomy 18 and 1q12~23 Amplification
4015 - The Antimalarial Agent Artesunate Overcomes Bortezomib Resistance in Myeloma Cell Lines Through Non-Caspase Mediated Apoptosis
193 - Metaphase Cytogenetic Abnormality (CA) Subtypes in Multiple Myeloma (MM) Treated with Front Line Total Therapy (TT) Protocols TT1, TT2, TT3, TT4 and TT5
195 - Identifying the Outliers Among Gene Expression Profiling (GEP)-Defined Low-Risk Myeloma Patients Treated with Total Therapy 2 and 3 (TT2, TT3)
198 - Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies in Complete Remission (BMB-CR) of Multiple Myeloma (MM) Patients Treated On Total Therapy Protocols – Normalization of GEP Signature in Comparison with Normal Donor BMB (BMB-NL) and Consequences for Progression-Free Survival (PFS)
324 - Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs
579 - Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients
1458 - Fulminant Onset of Acute Leukemia (FOAL) After Total Therapies (TT) for Multiple Myeloma (MM): Absence of MDS Pathological Criteria within 3 Months of Prior MM Follow-up
1850 - Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66
1912 - Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order
1962 - Renal Function Impairment (creatinine>=2mg/dL) Limits Progress Noted with the Transition From Total Therapies TT1 to TT2 to TT3 Across Age Groups
2925 - Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma
2933 - Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression
3940 - High CCN1 Levels Are Associated with Longer Progression-Free and Overall Survival in GEP-Defined High-Risk Myeloma
3953 - Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies (BMB) in Multiple Myeloma (MM) – Relationship to Plasma-Cell (PC)-Based GEP-Defined Risk and Molecular Subgroups
3976 - Abnormal Hevylite Assay Ratio As a Prognostic Marker for Survival in Newly Diagnosed Multiple Myeloma Patients Treated On Total Therapy 3
4008 - Carfilzomib Induces Differentiation of Mesenchymal Stromal Cells Toward Osteoblast Via Activation of β-Catenin/TCF Signaling
4020 - Myeloma Can Modulate Expanded Natural Killer Cell Function Through Multiple Mechanisms
4083 - Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)
1815 - Reduced HMOX1 Expression in Myelomatous Bones Is Associated with Poor Survival and Its Induction Regulates Osteoclastogenesis and Osteoblastogenesis
2944 - HMOX1 Is a Targeted Therapy for Myeloma-Induced Bone Disease